Quanterix Corporation Common Stock (QTRX) Stock Price
QTRXStock
$2.87−51.76%52W
Market Cap$135.73M
P/E—
PEG Ratio—
Div yield—
Beta0.99
QTRX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-25.24%
Price vs S&P 500 (4W)-4.27%
VGM Score62.74
QTRX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.41 | -$1.04 | -153.66%(-$0.63) | |
| Q1 2026 | -$0.62 | $0.16 | +126.29%(+$0.78) | |
| Q4 2025 | -$0.48 | -$0.47 | +2.08%(+$0.01) | |
| Q3 2025 | -$0.53 | -$0.73 | -37.74%(-$0.20) | |
| Q2 2025 | -$0.41 | -$0.77 | -88.96%(-$0.36) |
QTRX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
2.38
2.38
2.38
2.38
Industry Peers — Lab Analytical Instruments(25)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
QTRXQuanterix Corporation Common Stock | A | B | D | 0.9x | 10.0% | 42.7% | -99.7% | $2.87 |
| AAgilent Technologies Inc. | D | C | A | 6.6x | 5.4% | 53.9% | 22.2% | $172.97 |
| WATWaters Corp | F | C | A | 9.4x | 6.0% | 50.9% | 7.1% | $436.95 |
| ILMNIllumina Inc | D | D | A | 8.8x | 6.0% | 66.4% | 19.5% | $262.54 |
| MTDMettler-Toledo International | D | C | A | 7.9x | 5.5% | 60.3% | 26.6% | $1622.29 |
| RVTYRevvity, Inc. | D | D | A | 5.8x | -5.5% | 55.0% | 12.3% | $152.64 |
| AVTRAvantor, Inc. | C | F | A | 1.7x | 0.5% | 31.8% | -4.7% | $16.42 |
| BIO.BBio-Rad Laboratories, Inc. Class B | C | D | B | 3.7x | 0.3% | 51.9% | 1.8% | $364.15 |
| BIOBio-Rad Laboratories, Inc.Class A | C | D | B | 3.7x | 0.3% | 51.9% | 1.8% | $353.70 |
| TXG10x Genomics, Inc. Class A Common Stock | F | D | A | 14.8x | 16.6% | 69.6% | -14.3% | $69.86 |
| BRKRBruker Corporation | D | D | B | 2.4x | 11.6% | 47.7% | -1.5% | $54.80 |
About Quanterix Corporation Common Stock
Quanterix Corp develops ultra-sensitive digital immunoassay platforms that detect protein biomarkers at concentrations undetectable by conventional technologies. The company's Simoa platform enables precision diagnostics and life sciences research across multiple therapeutic areas, supported by a suite of instruments, assays, and laboratory services. With a global presence spanning North America, EMEA, and Asia Pacific, Quanterix serves the growing market for advanced biomarker detection in healthcare and research.